| 1. |
- Boutajangout, Allal, et al.
(författare)
-
Affibody-Mediated Sequestration of Amyloid beta Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model
- 2019
-
Ingår i: Frontiers in Aging Neuroscience. - : Frontiers Media S.A.. - 1663-4365 .- 1663-4365. ; 11
-
Tidskriftsartikel (refereegranskat)abstract
- Different strategies for treatment and prevention of Alzheimer's disease (AD) are currently under investigation, including passive immunization with anti-amyloid beta (anti-A beta) monoclonal antibodies (mAbs). Here, we investigate the therapeutic potential of a novel type of A beta-targeting agent based on an affibody molecule with fundamentally different properties to mAbs. We generated a therapeutic candidate, denoted Z(SYM73)-albumin-binding domain (ABD; 16.8 kDa), by genetic linkage of the dimeric Z(SYM73) affibody for sequestering of monomeric A beta-peptides and an ABD for extension of its in vivo half-life. Amyloid precursor protein (APP)/PS1 transgenic AD mice were administered with Z(SYM73)-ABD, followed by behavioral examination and immunohistochemistry. Results demonstrated rescued cognitive functions and significantly lower amyloid burden in the treated animals compared to controls. No toxicological symptoms or immunology-related side-effects were observed. To our knowledge, this is the first reported in vivo investigation of a systemically delivered scaffold protein against monomeric A beta, demonstrating a therapeutic potential for prevention of AD.
|
|
| 2. |
- Ekblad, Caroline, et al.
(författare)
-
Polypeptides based on a scaffold
- 2022
-
Patent (populärvet., debatt m.m.)abstract
- The disclosure provides a population of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence Xsc1AELDXsc2Xsc3GVG AXXIKXIXsc4XA XXVEXVQXXK QXILAX. The disclosure also provides methods for selecting and identifying polypeptides from the population, as well as such polypeptides themselves.
|
|
| 3. |
- Fleetwood, Filippa, et al.
(författare)
-
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity
- 2014
-
Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 4, s. 7518-
-
Tidskriftsartikel (refereegranskat)abstract
- Angiogenesis plays an important role in cancer and ophthalmic disorders such as age-related macular degeneration and diabetic retinopathy. The vascular endothelial growth factor (VEGF) family and corresponding receptors are regulators of angiogenesis and have been much investigated as therapeutic targets. The aim of this work was to generate antagonistic VEGFR2-specific affinity proteins having adjustable pharmacokinetic properties allowing for either therapy or molecular imaging. Two antagonistic Affibody molecules that were cross-reactive for human and murine VEGFR2 were selected by phage and bacterial display. Surprisingly, although both binders independently blocked VEGF-A binding, competition assays revealed interaction with non-overlapping epitopes on the receptor. Biparatopic molecules, comprising the two Affibody domains, were hence engineered to potentially increase affinity even further through avidity. Moreover, an albumin-binding domain was included for half-life extension in future in vivo experiments. The best-performing of the biparatopic constructs demonstrated up to 180-fold slower dissociation than the monomers. The new Affibody constructs were also able to specifically target VEGFR2 on human cells, while simultaneously binding to albumin, as well as inhibit VEGF-induced signaling. In summary, we have generated small antagonistic biparatopic Affibody molecules with high affinity for VEGFR2, which have potential for both future therapeutic and diagnostic purposes in angiogenesis-related diseases.
|
|
| 4. |
- Grönwall, Caroline, et al.
(författare)
-
Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides
- 2007
-
Ingår i: Journal of Biotechnology. - : Elsevier BV. - 0168-1656 .- 1873-4863. ; 128:1, s. 162-183
-
Tidskriftsartikel (refereegranskat)abstract
- Affibody (Affibody) ligands specific for human amyloid beta (Abeta) peptides (40 or 42 amino acid residues in size), involved in the progress of Alzheimer's disease, were selected by phage display technology from a combinatorial protein library based on the 58-amino acid residue staphylococcal protein A-derived Z domain. Post-selection screening of 384 randomly picked clones, out of which 192 clones were subjected to DNA sequencing and clustering, resulted in the identification of 16 Affibody variants that were produced and affinity purified for ranking of their binding properties. The two most promising Affibody variants were shown to selectively and efficiently bind to Abeta peptides, but not to the control proteins. These two Affibody ligands were in dimeric form (to gain avidity effects) coupled to affinity resins for evaluation as affinity devices for capture of Abeta peptides from human plasma and serum. It was found that both ligands could efficiently capture Abeta that were spiked (100 microgml(-1)) to plasma and serum samples. A ligand multimerization problem that would yield suboptimal affinity resins, caused by a cysteine residue present at the binding surface of the Affibody ligands, could be circumvented by the generation of second-generation Affibody ligands (having cysteine to serine substitutions). In an epitope mapping effort, the preferred binding site of selected Affibody ligands was mapped to amino acids 30-36 of Abeta, which fortunately would indicate that the Affibody molecules should not bind the amyloid precursor protein (APP). In addition, a significant effort was made to analyze which form of Abeta (monomer, dimer or higher aggregates) that was most efficiently captured by the selected Affibody ligand. By using Western blotting and a dot blot assay in combination with size exclusion chromatography, it could be concluded that selected Affibody ligands predominantly bound a non-aggregated form of analyzed Abeta peptide, which we speculate to be dimeric Abeta. In conclusion, we have successfully selected Affibody ligands that efficiently capture Abeta peptides from human plasma and serum. The potential therapeutic use of these optimized ligands for extracorporeal capture of Abeta peptides in order to slow down or reduce amyloid plaque formation, is discussed.
|
|
| 5. |
- Gunneriusson, Elin
(författare)
-
Display of affinity proteins on bacteria and bacteriophage
- 1999
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Surface display of peptides and proteins on microorganismshas during the last decade gained tremendous interest due tothe numerous applications for the technique found inbiotechnology, molecular biology and immunology. This thesisdescribes both bacterial display of different affinity proteinsand display of libraries of small α-helical proteindomains on phage for selection of novel binding proteinsdenoted affibodies.A single chain Fv (scFv) antibody fragment, directed againsthuman immunoglobulin E (IgE), was surface displayed on the twofood-grade staphylococcal speciesStaphylococcus xylosusandStaphylococcus carnosus, using two different expressionsystems both taking advantage of the cell wall anchoring partsof staphylococcal protein A (SpA). Heterologous,scFv-containing hybrid proteins were found to be surfaceexposed on both cell types and the whole live bacterial cellswere shown to have gained ability to bind the target antigen,human IgE.Combinatorial libraries of a 58 residue, alpha-helicaldomain derived from a SpA analogue have been monovalentlydisplayed on phage as fused to a truncated protein III of M13bacteriophages. The immunoglobulin G (IgG) Fc binding surfaceof the native domain was targeted for randomization to createlarge libraries of domain variants from which new proteins,affibodies, with novel binding specificities, could beselected. Identified affibodies directed against apolipoproteinA-1MilanoandTaqDNA polymerase, respectively, were shown toselectively bind their targets and could efficiently be used asligands in affinity chromatography to purify the targetproteins from crude lysates ofE. colicells. In addition, a high stability againstalkaline conditions was demonstrated in column sanitation stepsusing sodium hydroxide. The affinities (KD) of affibodies selected from naive libraries wereroutinely in the micromolar range, although with differentkinetic characteristics. Using a helix shuffling affinitymaturation strategy, the affinity of aTaqDNA polymerase specific affibody could be improved15-fold. Head to tail genetic fusion, yielding a divalentmolecule, was demonstrated to further increase the apparentaffinity by avidity effects.Two different affibodies, reactive with human IgA or IgE,respectively, were surface exposed onS. carnosususing the expression system employed for thescFv antibody. The affibodies were demonstrated to beproteolytically stable and efficiently and functionallydisplayed on the staphylococcal surface.Taken together, it has been demonstrated that small andhighly stable α-helical affibody domains, normally bindingto IgG, can be randomized in surface-exposed positions to yieldlarge combinatorial libraries from which new variants can beselected with redirected binding specificities. Furthermore,staphylococcal surface display of such SpA-derived affibodies,or the variable parts of an antibody linked as a scFv, has beenshown to generate recombinant bacteria with new bindingspecificities, that could for example be investigated as novelwhole cell diagnostic devices.Keywords:affibody, affinity chromatography, affinitymaturation, bacterial surface display,in vitroselection, combinatorial protein library, phagedisplay, scFv antibody fragment, staphylococcal protein A,Staphylococcus carnosus, Staphylococcus xylosus,Zdomain.© Elin Gunneriusson,1999
|
|
| 6. |
- Honarvar, Hadis, et al.
(författare)
-
Imaging of CAIX-expressing xenografts in vivo using 99mTc-HEHEHE-ZCAIX : 1 Affibody molecule
- 2015
-
Ingår i: International Journal of Oncology. - : Spandidos Publications. - 1019-6439 .- 1791-2423. ; 46:2, s. 513-20
-
Tidskriftsartikel (refereegranskat)abstract
- Carbonic anhydrase IX (CAIX) is a transmembrane enzyme involved in regulation of tissue pH balance. In cancer, CAIX expression is associated with tumor hypoxia. CAIX is also overexpressed in renal cell carcinoma and is a molecular target for the therapeutic antibody cG250 (girentuximab). Radionuclide imaging of CAIX expression might be used for identification of patients who may benefit from cG250 therapy and from treatment strategies for hypoxic tumors. Affibody molecules are small (7 kDa) scaffold proteins having a high potential as probes for radionuclide molecular imaging. The aim of the present study was to evaluate feasibility of in vivo imaging of CAIX-expression using radiolabeled Affibody molecules. A histidine-glutamate-histidine-glutamate-histidine-glutamate (HE)3-tag-containing CAIX-binding Affibody molecule (HE)3-ZCAIX:1 was labeled with [99mTc(CO)3]+. Its binding properties were evaluated in vitro using CAIX-expressing SK-RC-52 renal carcinoma cells. 99mTc-(HE)3-ZCAIX:1 was evaluated in NMRI nu/nu mice bearing SK-RC-52 xenografts. The in vivo specificity test confirmed CAIX-mediated tumor targeting. 99mTc-(HE)3-ZCAIX:1 cleared rapidly from blood and normal tissues except for kidneys. At optimal time-point (4 h p.i.), the tumor uptake was 9.7±0.7% ID/g, and tumor-to-blood ratio was 53±10. Experimental imaging of CAIX-expressing SK-RC-52 xenografts at 4 h p.i. provided high contrast images. The use of radioiodine label for ZCAIX:1 enabled the reduction of renal uptake, but resulted in significantly lower tumor uptake and tumor-to-blood ratio. Results of the present study suggest that radiolabeled Affibody molecules are promising probes for imaging of CAIX-expression in vivo.
|
|
| 7. |
- Klint, Susanne, et al.
(författare)
-
Izokibep : Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
- 2023
-
Ingår i: mAbs. - : Taylor & Francis. - 1942-0862 .- 1942-0870. ; 15:1
-
Tidskriftsartikel (refereegranskat)abstract
- Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatment with monoclonal antibodies (mAbs) against IL-17A provides an improvement in the Psoriasis Area and Severity Index compared to conventional systemic agents. In this study, the Affibody(CIRCLED LATIN CAPITAL LETTER R) technology was used to identify and optimize a novel, small, biological molecule comprising three triple helical affinity domains, izokibep (previously ABY-035), for the inhibition of IL-17A signaling. Preclinical studies show that izokibep, a small 18.6 kDa IL-17 ligand trap comprising two IL-17A-specific Affibody domains and one albumin-binding domain, selectively inhibits human IL-17A in vitro and in vivo with superior potency and efficacy relative to anti-IL-17A mAbs. A Phase 1 first-in-human study was conducted to establish the safety, pharmacokinetics, and preliminary efficacy of izokibep, when administered intravenously and subcutaneously as single doses to healthy subjects, and as single intravenous and multiple subcutaneous doses to patients with psoriasis (NCT02690142; EudraCT No: 2015-004531-13). Izokibep was well tolerated with no meaningful safety concerns identified in healthy volunteers and patients with psoriasis. Rapid efficacy was seen in all psoriasis patients after one dose which further improved in patients receiving multiple doses. A therapeutic decrease in joint pain was also observed in a single patient with concurrent psoriatic arthritis. The study suggests that izokibep has the potential to safely treat IL17A-associated diseases such as psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis.
|
|
| 8. |
- Kronqvist, Nina, et al.
(författare)
-
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules
- 2011
-
Ingår i: Protein Engineering Design & Selection. - : Oxford University Press (OUP). - 1741-0126 .- 1741-0134. ; 24:4, s. 385-396
-
Tidskriftsartikel (refereegranskat)abstract
- Emerging evidence suggests that the catalytically inactive ErbB3 (HER3) protein plays a fundamental role in normal tyrosine kinase receptor signaling as well as in aberrant functioning of these signaling pathways, resulting in several forms of human cancers. ErbB3 has recently also been implicated in resistance to ErbB2-targeting therapies. Here we report the generation of high-affinity ErbB3-specific Affibody molecules intended for future molecular imaging and biotherapeutic applications. Using a high-complexity phage-displayed Affibody library, a number of ErbB3 binders were isolated and specific cell-binding activity was demonstrated in immunofluorescence microscopic studies. Subsequently, a second-generation library was constructed based on sequences of the candidates from the phage display selection. By exploiting the sensitive affinity discrimination capacity of a novel bacterial surface display technology, the affinity of candidate Affibody molecules was further increased down to subnanomolar affinity. In summary, the demonstrated specific targeting of native ErbB3 receptor on human cancer cell lines as well as competition with the heregulin/ErbB3 interaction indicates that these novel biological agents may become useful tools for diagnostic and therapeutic targeting of ErbB3-expressing cancers. Our studies also highlight the powerful approach of combining the advantages of different display technologies for generation of functional high-affinity protein-based binders. Potential future applications, such as radionuclide-based diagnosis and treatment of human cancers are discussed.
|
|
| 9. |
- Lindbo, Sarah, et al.
(författare)
-
Design, construction and characterization of an ABD-based library with improved stability
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Recombinant affinity proteins binding specifically to other molecules are important tools for many clinical and industrial applications. Small robust protein scaffolds have proven to be well suited as frameworks for generation of novel affinity binders due to their stability. Here we used the albumin-binding domain (ABD) of protein G from Streptococcus G148 as scaffold to design a new combinatorial library capable of generating stable binders to various target proteins with high affinity and specificity. To create a robust framework able to generate highly stable binders, mutations in the non-binding region were evaluated and residues providing increased stability were introduced into the scaffold. By combining rational design with combinatorial protein engineering we also evaluated the surface exposed amino acids at the albumin-binding interface and identified 11 residues suitable for randomization. The potency of the novel scaffold library was assessed by screening for binders using phage display against three distinct targets; complement factor 4, (C4), insulin and interleukin-6 (IL-6). Binders in the nanomolar range with melting temperature above 57°C were selected for all three targets. Notably, the identified IL-6 binders were characterized by extreme thermal stability with variants demonstrating organized structures even at 90°C. This demonstrates that stable binders with distinct specificities can be generated and thus proves the high potential of the library.
|
|
| 10. |
- Parks, Luke, et al.
(författare)
-
Directed evolution of an affibody molecule for carbonic anhydrase IX using E. coli display and fluorescence-activated cell sorting
-
Annan publikation (övrigt vetenskapligt/konstnärligt)abstract
- Carbonic anhydrase IX (CAIX) is a transmembrane enzyme that plays an important role in pH regulation and cellular homeostasis. Overexpression of CAIX is commonly observed in various solid tumors, making it an attractive target for cancer therapy. Affibody molecules have previously been developed for CAIX and demonstrated potential as tracers for molecular imaging in murine xenografted tumor models. Here, we further develop such affibody molecules by displaying a designed affibody library on the surface of Escherichia coli, followed by isolation of CAIX-binding variants by a combination of magnetic-assisted cell sorting and fluorescence-activated cell sorting. The sortings were successful and screening of candidates after selection revealed several variants with improved properties, most notably an increase in affinity and CAIX cell binding at 37°C and 42°C.
|
|
